Freight Tech [FRGT] - Last Close: $2.08
The parent company behind the Fr8App freight & logistics app just announced a new collaboration with Envases Universales.
Freight Tech said its Fr8App was awarded key routes through Evases’ annual 2024 RF.
Over the next 12 months, the awards could be worth upwards of $5 million and encompass 24 dedicated lanes, mostly from Mexico to the United States.
FRGT is up 21.1% on over 8 million shares traded.
My Take: FRGT’s announcement has some actual substance too it, and its chart shows that its recent downtrend could be bottoming out.
Interactive Strength [TRNR] - Last Close: $0.64
This tiny stock just announced an exclusive worldwide distribution agreement with WOODWAY USA to sell and distribute its CLMBR product.
Under the terms of the deal, WOODWAY will place an initial purchase of 2,150 units for an expected net proceed of $7 million for Interactive Strength.
TRNR is leading with a 96.9% gain on roughly 7 millions shares traded.
My Take: This could be a breakout deal for TRNR, but this is a micro-cap stock so expect volatility.
Ascent Solar Tech [ASTI] - Last Close: $0.6078
Ascent Solar just landed a game-changing deal to fly space solar modules on NASA’s upcoming LISA-T mission scheduled for Summer 2024.
The NASA mission will “demonstrate the capability to deploy large-area arrays on lightweight, low-cost and small spacecraft.”
Financial arrangements weren’t disclosed, but ASTI is up 38.2% on over 9 million shares traded so far.
My Take: A buzz is building around the space sector, and ASTI is cashing in on the momentum with this news. However, this tiny stock might not be able to sustain these gains.
Zyversa Therapeutics [ZVSA] - Last Close: $0.8010
After publishing a new white paper highlighting therapeutic opportunities for neurological diseases last week, Zyversa is surging in today’s premarket.
The white paper was published last Thursday morning, and it discussed the role of inflammasomes and ASC specks in neurological diseases.
Zyversa also provided data supporting its inflammasome ASC Inhibitor IC 100 as a potential therapeutic option.
ZVSA closed out last week with a 29.1% gain on Friday, and it’s up 89.7% on more than 17 million shares traded in today’s premarket.
My Take:ZVSA seems to be having a bit of delayed reaction to last week’s white paper, but there are no other obvious catalysts to explain the stock’s sudden run-up.
